Wall Street analyst estimates for Mirum Pharmaceuticals, Inc. (MIRM): consensus price target, buy/hold/sell recommendations and forecasts for revenue, EPS and EBITDA for the upcoming fiscal years.
Mirum Pharmaceuticals, Inc. is a biopharmaceutical firm dedicated to discovering and commercializing groundbreaking therapies for serious rare and orphan conditions. Its lead experimental drug, LIVMARLI, an oral treatment, is currently undergoing trials for progressive familial intrahepatic cholestasis (PFIC), Alagille syndrome, and biliary atresia.
Analyst Consensus
| Strong Buy | 1 |
| Buy | 17 |
| Hold | 0 |
| Sell | 0 |
| Strong Sell | 0 |
| Total analysts | 18 |
| Avg rating (1-5) | 1.06 |
Recent Earnings Surprises
| Date | EPS Actual | EPS Est. | vs Est. |
|---|---|---|---|
| 2026-11-03 | $-0.53 | ||
| 2026-08-05 | $-1.06 | $-0.74 | -42.8% |
| 2026-05-06 | $-13.43 | $-0.40 | -3257.5% |
| 2026-02-25 | $-0.11 | $0.02 | -650.0% |
| 2025-11-04 | $0.05 | $-0.10 | +150.0% |
| 2025-08-06 | $-0.12 | $-0.31 | +61.3% |
| 2025-05-07 | $-0.30 | $-0.39 | +23.1% |
| 2025-02-26 | $-0.49 | $-0.27 | -81.5% |
Valuation Ratios
| Price / Book | -565.87 |
| EV / EBITDA | -7.92 |
| Dividend Yield | 0.00% |
Income Statement (10y)
| Year | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|
| Revenue | 0 | 0 | 0 | $19.1M | $77.1M | $186.4M | $336.9M | $521.3M |
| Cost of Revenue | 0 | $324000 | $623000 | $1.9M | $12.4M | $47.0M | $81.6M | $100.6M |
| Gross Profit | 0 | -$324000 | -$623000 | $17.2M | $64.7M | $139.3M | $255.2M | $420.7M |
| Research & Development | $2.3M | $43.0M | $81.6M | $131.4M | $106.8M | $102.6M | $140.6M | $186.2M |
| Selling, General & Admin | $585000 | $11.8M | $22.7M | $59.2M | $89.1M | $145.9M | $202.2M | $257.0M |
| Operating Expenses | $2.9M | $54.7M | $103.7M | $190.6M | $195.9M | $248.5M | $342.9M | $443.2M |
| Operating Income | -$2.9M | -$54.7M | -$104.3M | -$173.4M | -$131.2M | -$109.2M | -$87.6M | -$22.1M |
| EBITDA | -$17.3M | -$52.2M | -$102.3M | -$65.4M | -$122.9M | -$136.5M | -$49.0M | $17.2M |
| Interest Expense | 0 | 0 | $335000 | $17.6M | $16.0M | $15.1M | $14.3M | $14.4M |
| Pre-tax Income | -$17.3M | -$52.5M | -$103.3M | -$84.0M | -$142.1M | -$162.4M | -$86.9M | -$21.4M |
| Income Tax | 0 | $21000 | $6000 | $37000 | -$6.4M | $991000 | $1.0M | $1.9M |
| Net Income | -$17.3M | -$52.6M | -$103.3M | -$84.0M | -$135.7M | -$163.4M | -$87.9M | -$23.4M |
| EPS | $-0.75 | $-2.29 | $-4.09 | $-2.77 | $-4.01 | $-4.00 | $-1.85 | $-0.47 |
| EPS (Diluted) | $-0.75 | $-2.29 | $-4.09 | $-2.77 | $-4.02 | $-4.00 | $-1.85 | $-0.47 |
| Shares Outstanding (Diluted) | $23.0M | $23.0M | $25.3M | $30.3M | $34.0M | $40.9M | $47.5M | $50.2M |
Price
| Price | $97.37 |
| Market Cap | $5.9B |
| Exchange | NASDAQ |
| Country | US |
Related companies: ACAD · ADMA · BLTE · DYN · LGND · PRAX · RARE
Explore sector: Healthcare · Biotechnology
More sections of MIRM: Overview · Financials · Valuation · Statistics · Technical · Ownership · News · Events
Discover more: Radar — undervalued stock signals · Investment Academy — learn to analyze stocks